279 related articles for article (PubMed ID: 34743503)
1. Mucopolysaccharidosis III: Molecular basis and treatment.
Spahiu L; Behluli E; Peterlin B; Nefic H; Hadziselimovic R; Liehr T; Temaj G
Pediatr Endocrinol Diabetes Metab; 2021; 27(3):201-208. PubMed ID: 34743503
[TBL] [Abstract][Full Text] [Related]
2. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
[TBL] [Abstract][Full Text] [Related]
3. Glycosaminoglycans and mucopolysaccharidosis type III.
Jakobkiewicz-Banecka J; Gabig-Ciminska M; Kloska A; Malinowska M; Piotrowska E; Banecka-Majkutewicz Z; Banecki B; Wegrzyn A; Wegrzyn G
Front Biosci (Landmark Ed); 2016 Jun; 21(7):1393-409. PubMed ID: 27100513
[TBL] [Abstract][Full Text] [Related]
4. Validation of Liquid Chromatography-Tandem Mass Spectrometry-Based 5-Plex Assay for Mucopolysaccharidoses.
Oguni T; Tomatsu S; Tanaka M; Orii K; Fukao T; Watanabe J; Fukuda S; Notsu Y; Vu DC; Can TBN; Nagai A; Yamaguchi S; Taketani T; Gelb MH; Kobayashi H
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32188102
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses.
Minami K; Morimoto H; Morioka H; Imakiire A; Kinoshita M; Yamamoto R; Hirato T; Sonoda H
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233030
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW
Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322
[TBL] [Abstract][Full Text] [Related]
7. Competitive binding of extracellular accumulated heparan sulfate reduces lysosomal storage defects and triggers neuronal differentiation in a model of Mucopolysaccharidosis IIIB.
De Pasquale V; Scerra G; Scarcella M; D'Agostino M; Pavone LM
Biochim Biophys Acta Mol Cell Res; 2021 Oct; 1868(11):119113. PubMed ID: 34329663
[TBL] [Abstract][Full Text] [Related]
8. Caprine mucopolysaccharidosis-IIID: clinical, biochemical, morphological and immunohistochemical characteristics.
Jones MZ; Alroy J; Boyer PJ; Cavanagh KT; Johnson K; Gage D; Vorro J; Render JA; Common RS; Leedle RA; Lowrie C; Sharp P; Liour SS; Levene B; Hoard H; Lucas R; Hopwood JJ
J Neuropathol Exp Neurol; 1998 Feb; 57(2):148-57. PubMed ID: 9600207
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and molecular analysis of mucopolysaccharidoses in Turkey.
Emre S; Terzioğlu M; Coşkun T; Tokath A; Ozalp I; Müller V; Hopwood J
Turk J Pediatr; 2002; 44(1):13-7. PubMed ID: 11858372
[TBL] [Abstract][Full Text] [Related]
10. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
[TBL] [Abstract][Full Text] [Related]
11. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.
Derrick-Roberts A; Kaidonis X; Jackson MR; Liaw WC; Ding X; Ong C; Ranieri E; Sharp P; Fletcher J; Byers S
Mol Genet Metab; 2020; 131(1-2):197-205. PubMed ID: 32739280
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of novel genetic variants in the first Chinese family of mucopolysaccharidosis IIIC (Sanfilippo C syndrome).
Zhao H; Wang L; Zhang M; Wang H; Zhang S; Wu J; Tang Y
J Cell Mol Med; 2024 Apr; 28(8):e18307. PubMed ID: 38613342
[TBL] [Abstract][Full Text] [Related]
14. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of intracellular amyloid-beta peptide (A beta 1-40) in mucopolysaccharidosis brains.
Ginsberg SD; Galvin JE; Lee VM; Rorke LB; Dickson DW; Wolfe JH; Jones MZ; Trojanowski JQ
J Neuropathol Exp Neurol; 1999 Aug; 58(8):815-24. PubMed ID: 10446806
[TBL] [Abstract][Full Text] [Related]
16. Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
Wilkinson FL; Holley RJ; Langford-Smith KJ; Badrinath S; Liao A; Langford-Smith A; Cooper JD; Jones SA; Wraith JE; Wynn RF; Merry CL; Bigger BW
PLoS One; 2012; 7(4):e35787. PubMed ID: 22558223
[TBL] [Abstract][Full Text] [Related]
17. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
Lau AA; Hemsley KM
J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346
[TBL] [Abstract][Full Text] [Related]
18. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
[TBL] [Abstract][Full Text] [Related]
19. Estimated birth prevalence of mucopolysaccharidoses in Brazil.
Federhen A; Pasqualim G; de Freitas TF; Gonzalez EA; Trapp F; Matte U; Giugliani R
Am J Med Genet A; 2020 Mar; 182(3):469-483. PubMed ID: 31926052
[TBL] [Abstract][Full Text] [Related]
20. Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.
Losada Díaz JC; Cepeda Del Castillo J; Rodriguez-López EA; Alméciga-Díaz CJ
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
